U.S. FDA ODAC Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study February 26, 2024
First Patient Dosed in Ph 1a Study with AVC-201 for the Treatment of R/R AML and other CD123 Heme Malignancies February 26, 2024
Immunocore and BMS to evaluate IMC-F106C (PRAME HLA-A02) + Opdivo in registrational Ph 3 1L melanoma trial February 26, 2024
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology February 26, 2024
Immune-Onc Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate IO-108 in Ph 1b/2 Study for 1L Treatment of HCC February 26, 2024
IND Applications approved by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors February 26, 2024
Dragonfly Announces Clinical Collaboration Exploring Combinations of DF1001 HER-2 TriNKET® with Trodelvy® in two Cancer Indications February 26, 2024
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics February 26, 2024
Erasca Announces Two Clinical Trial Collaboration & Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 & SEACRAFT-2 Trials February 26, 2024
US FDA approval of Onivyde® (Irinotecan Liposome Injection) + NALIRIFOX for 1L mPDAC triggers a $225M milestone payment from Ipsen to Merrimack February 26, 2024
ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage ADC Pipeline February 26, 2024
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash February 26, 2024
Medigene announces indication selection for the clinical development of its TCR-T therapy program in solid tumors February 26, 2024
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs February 26, 2024
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer February 26, 2024
Radiomedix and Orano Med Initiate Ph 2 Multi-Center Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers February 26, 2024
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Ph 3 Head and Neck Cancer Study February 26, 2024
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates February 26, 2024
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program February 26, 2024
FDA Accepts for Priority Review Supplemental NDA for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors February 26, 2024
Datopotamab deruxtecan BLA accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer February 26, 2024
FDA accepted for Priority Review the BLA for linvoseltamab for R/R multiple myeloma that has progressed after at least three prior therapies February 26, 2024
